Go to
current issue
加入关注
催更
样式： 排序： IF: - GO 导出 标记为已读
-
Computer-aided detection in real-world colonoscopy: enhancing detection or offering false hope? Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-06-01 Masashi Misawa, Shin-ei Kudo, Yuichi Mori
Abstract not available
-
Effect of real-time computer-aided detection of colorectal adenoma in routine colonoscopy (COLO-GENIUS): a single-centre randomised controlled trial Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-06-01 David Karsenti, Gaëlle Tharsis, Bastien Perrot, Philippe Cattan, Alice Percie du Sert, Franck Venezia, Elie Zrihen, Agnès Gillet, Jean-Philippe Lab, Gilles Tordjman, Maryan Cavicchi
Background Artificial intelligence systems have been developed to improve polyp detection. We aimed to evaluate the effect of real-time computer-aided detection (CADe) on the adenoma detection rate (ADR) in routine colonoscopy. Methods This single-centre randomised controlled trial (COLO-GENIUS) was done at the Digestive Endoscopy Unit, Pôle Digestif Paris-Bercy, Clinique Paris-Bercy, Charenton-le-Pont
-
Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-06-01 Mette Julsgaard, Uma Mahadevan, Thea Vestergaard, Raf Mols, Marc Ferrante, Patrick Augustijns
Abstract not available
-
Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-22 Jasmohan S Bajaj, Ashok K Choudhury, Qing Xie, Patrick S Kamath, Mark Topazian, Peter C Hayes, Aldo Torre, Hailemichael Desalegn, Ramazan Idilman, Zhujun Cao, Mario R Alvares-da-Silva, Jacob George, Brian J Bush, Leroy R Thacker, Florence Wong
Background Cirrhosis, the end result of liver injury, has high mortality globally. The effect of country-level income on mortality from cirrhosis is unclear. We aimed to assess predictors of death in inpatients with cirrhosis using a global consortium focusing on cirrhosis-related and access-related variables. Methods In this prospective observational cohort study, the CLEARED Consortium followed up
-
The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-22 Jasmijn Z Jagt, Patrick F van Rheenen, Sophia M A Thoma, Jonathan Gower, Pamela B Reimering-Hartgerink, Heidi J H L van der Wielen, Esther J van Steenbergen, Anne-Marije Goutbeek, Elisabeth M van Dijk-Lokkart, Stijn Vlietstra, Dana Reinders, Yanniek den Otter, Isabella Schoonderwoert, Bas Schoonderwoert, Hannie Schoonderwoert, Germa van der Weide, Simone van Harten, Kees Mouthaan, Marc A Benninga,
Abstract not available
-
A path to global cirrhosis health equity Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-22 Lauren D Nephew
Abstract not available
-
Financing viral hepatitis: catalysing action for impact Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-22 Jessica Hicks, Grace Singh, Capucine Penicaud, Kiira Gustafson, Cary James, Naomi Burke-Shyne, Colleen Daniels, Oriel Fernandes, Kimberly E Green, Benjamin Cowie, John W Ward, Teri Roberts, David Ruiz Villafranca
Abstract not available
-
DGBI overlap: a model for a transdiagnostic approach? Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-18 Micaela Atkins, Helen Burton Murray
Abstract not available
-
Overlap of disorders of gut–brain interaction: a systematic review and meta-analysis Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-18 Thomas Fairlie, Ayesha Shah, Nicholas J Talley, William D Chey, Natasha Koloski, Yeong Yeh Lee, Kok-Ann Gwee, Michael P Jones, Gerald Holtmann
Background Rome criteria differentiate distinct types of disorders of gut–brain interaction (DGBI); also known as functional gastrointestinal disorders. Overlap of symptom categories frequently occurs. This systematic review and meta-analysis aimed to define the prevalence of DGBI overlap and compare overlap in population-based, primary care or tertiary care health settings. Furthermore, we aimed to
-
AAV2 and severe acute hepatitis of unknown aetiology Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-10
Abstract not available
-
Reducing disparities in training in inflammatory bowel disease Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-10 Anuraag Jena, Vishal Sharma, Shaji Sebastian
Abstract not available
-
Antimicrobial susceptibility testing for Helicobacter pylori comes of age Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-10 Colm O'Morain, Sinead M Smith
Abstract not available
-
Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-10 Mei-Jyh Chen, Po-Yueh Chen, Yu-Jen Fang, Ming-Jong Bair, Chieh-Chang Chen, Chien-Chuan Chen, Tsung-Hua Yang, Ji-Yuh Lee, Chien-Chun Yu, Chia-Chi Kuo, Min-Chin Chiu, Chu-Kuang Chou, Chi-Yi Chen, Wen-Hao Hu, Min-Horn Tsai, Yao-Chun Hsu, Chia-Tung Shun, Jiing-Chyuan Luo, Jaw-Town Lin, Emad M El-Omar, Jyh-Ming Liou
Background Helicobacter pylori infection is an important causal factor of gastric cancer and peptic ulcer disease and is associated with immune thrombocytopenic purpura and functional dyspepsia. In H pylori strains, point mutations in the 23S rRNA and gyrA genes are associated with clarithromycin resistance and levofloxacin resistance, respectively. Whether the efficacy of molecular testing-guided
-
Outcomes of minimum unit pricing for alcohol in Scotland Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-10
Abstract not available
-
Equality, diversity, and inclusion in UK gastroenterology Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-10 Andrew Veitch
Abstract not available
-
Correction to Lancet Gastroenterol Hepatol 2022; 7: 522–32 Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-10
Abstract not available
-
Research in Brief Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-10 Holly Baker
Abstract not available
-
Are postbiotics key to the potential benefits of fermented foods? Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-10 Paul Gill, Heidi M Staudacher
Abstract not available
-
Breaking the bathroom stigma on Channel 4 Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-10 Stephanie C Becker
Abstract not available
-
Lowering costs: the golden rule for achieving WHO goals Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-05 Yi-Fen Shih, Chun-Jen Liu
Abstract not available
-
Impact and cost-effectiveness of hepatitis B virus prophylaxis in pregnancy: a dynamic simulation modelling study Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-05 Shevanthi Nayagam, Margaret J de Villiers, Yusuke Shimakawa, Maud Lemoine, Mark R Thursz, Nick Walsh, Timothy B Hallett
Background In 2020, WHO recommended the addition of peripartum antiviral prophylaxis (PAP) to hepatitis B birth dose vaccination (HepB-BD) and hepatitis B infant vaccination (HepB3) to reduce mother-to-child transmission of hepatitis B virus (HBV) infection in pregnant women who have a marker of high infectivity (ie, HBV DNA ≥200 000 international units per mL or HBeAg-positive). We aimed to evaluate
-
Regional variation in characteristics of patients with decompensated cirrhosis admitted to hospitals in the UK Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-05-03
Abstract not available
-
Fatty change of the pancreas: the Pandora's box of pancreatology Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-21 Maxim S Petrov
Prevention of common diseases of the pancreas or interception of their progression is as attractive in theory as it is elusive in practice. The fundamental challenge has been an incomplete understanding of targets coupled with a multitude of intertwined factors that are associated with the development of pancreatic diseases. Evidence over the past decade has shown unique morphological features, distinctive
-
How do global trends in Helicobacter pylori prevalence inform prevention planning? Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-20 Julia Butt, Meira Epplein
Abstract not available
-
Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-20 Yunhao Li, Horace Choi, Kathy Leung, Fang Jiang, David Y Graham, Wai K Leung
Background Few studies have examined the temporal trends of Helicobacter pylori prevalence worldwide. We aimed to identify the changes in global prevalence of H pylori infection between 1980 and 2022. Methods In this systematic review and meta-analysis, we searched PubMed, Embase, MEDLINE, Scopus, and Web of Science, with no language restrictions, for observational studies on the prevalence of H pylori
-
US Government plans overhaul of organ transplantation system Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-18 Bryant Furlow
Abstract not available
-
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-13 Monica A Tincopa, Rohit Loomba
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent form of chronic liver disease that poses challenges in diagnosis and risk stratification. Non-alcoholic steatohepatitis (NASH), the more progressive form of NAFLD, is particularly challenging to diagnose in the absence of histology. Liver biopsy is infrequently performed due to its invasive nature, potential for sampling error, and lack
-
Diagnosis of fatty liver in children should occur in parallel to investigation for other causes of liver disease Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-04
Abstract not available
-
The economic burden of inflammatory bowel disease Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-05
Abstract not available
-
Trends in alcohol-specific deaths in the UK and industry responses Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-05 Nason Maani, May CI van Schalkwyk, Mark Petticrew
Abstract not available
-
Treatment de-escalation in Crohn's disease Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-05 Cathy McShane, David Kevans
Abstract not available
-
Treatment de-escalation in Crohn's disease – Author's reply Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-05 Edouard Louis
Abstract not available
-
$11 billion US hepatitis C elimination plan proposed Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-05 Bryant Furlow
Abstract not available
-
18th Congress of the European Crohn's and Colitis Organisation Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-05 Rob Brierley
Abstract not available
-
Research in Brief Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-05 Holly Baker
Abstract not available
-
Marc Rothenberg: passionately curious Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-05 Jennifer Thorley
Abstract not available
-
The War Inside Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-05 Georgia Bisbas
Abstract not available
-
Effect of the COVID-19 pandemic on endoscopic surveillance in Lynch syndrome in the Netherlands Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-04-05 Elsa L S A van Liere, Nanne K H de Boer, Ezra A Parsan, Monique E van Leerdam, Dewkoemar Ramsoekh
Abstract not available
-
Status of HBV birth dose vaccination in Africa: the impact of COVID-19 and Gavi support on policy development Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-27 Henry N Njuguna, Lindsey Hiebert, Neil Gupta, John W Ward
Abstract not available
-
Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-27 Adelina Artenie, Jack Stone, Hannah Fraser, Daniel Stewart, Chiedozie Arum, Aaron G Lim, Anna L McNaughton, Adam Trickey, Zoe Ward, Daniela Abramovitz, Michel Alary, Jacquie Astemborski, Julie Bruneau, Steven J Clipman, Carla S Coffin, Sara Croxford, Kora DeBeck, Eva Emanuel, Kanna Hayashi, Joumana G Hermez, Ernst Wisse
Background Measuring the incidence of HIV and hepatitis C virus (HCV) infection among people who inject drugs (PWID) is key to track progress towards elimination. We aimed to summarise global data on HIV and primary HCV incidence among PWID and associations with age and sex or gender. Methods In this systematic review and meta-analysis, we updated an existing database of HIV and HCV incidence studies
-
The road to HIV and HCV elimination among people who inject drugs Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-27 Diana Corona-Mata, Antonio Rivero-Juarez
Abstract not available
-
Top 10 research priorities for irritable bowel syndrome: results of a James Lind Alliance priority setting partnership Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-27 Christopher J Black, Yvonne A McKenzie, Morgan Scofield-Marlowe, Peter Setter, Maryrose Tarpey, Alexander C Ford
Abstract not available
-
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-21 Yasaman Vali, Jenny Lee, Jerome Boursier, Salvatore Petta, Kristy Wonders, Dina Tiniakos, Pierre Bedossa, Andreas Geier, Sven Francque, Mike Allison, Georgios Papatheodoridis, Helena Cortez-Pinto, Raluca Pais, Jean-Francois Dufour, Diana Julie Leeming, Stephen A Harrison, Yu Chen, Jeremy F Cobbold, Michael Pavlides, Adriaan G Holleboom, Patrick M Bossuyt
Background The reference standard for detecting non-alcoholic steatohepatitis (NASH) and staging fibrosis—liver biopsy—is invasive and resource intensive. Non-invasive biomarkers are urgently needed, but few studies have compared these biomarkers in a single cohort. As part of the Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) project, we aimed to evaluate the diagnostic accuracy
-
The quest for the ideal NASH biomarker Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-21 Giada Sebastiani
Abstract not available
-
Semaglutide in NASH-related cirrhosis: too late to the party? Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-16 Fernando Bril
Abstract not available
-
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-16 Rohit Loomba, Manal F Abdelmalek, Matthew J Armstrong, Maximilian Jara, Mette Skalshøi Kjær, Niels Krarup, Eric Lawitz, Vlad Ratziu, Arun J Sanyal, Jörn M Schattenberg, Philip N Newsome
Background Patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis are at high risk of liver-related and all-cause morbidity and mortality. We investigated the efficacy and safety of the glucagon-like peptide-1 analogue semaglutide in patients with NASH and compensated cirrhosis. Methods This double-blind, placebo-controlled phase 2 trial enrolled patients from 38 centres in Europe and
-
Inflammation and malnutrition in inflammatory bowel disease Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-15 Sara Massironi, Chiara Viganò, Andrea Palermo, Lorena Pirola, Giacomo Mulinacci, Mariangela Allocca, Laurent Peyrin-Biroulet, Silvio Danese
Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, has become increasingly prevalent worldwide in the past decade. The nutritional status of patients with IBD is often impaired, with malnutrition presenting as imbalanced energy or nutrient intake, including protein-energy malnutrition, disease-related malnutrition, sarcopenia, and micronutrient deficiency. Additionally
-
A substantial advance for screening of oesophageal cancer Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-14 Sanford M Dawsey, Lucas C Duits
Abstract not available
-
Machine learning-based automated sponge cytology for screening of oesophageal squamous cell carcinoma and adenocarcinoma of the oesophagogastric junction: a nationwide, multicohort, prospective study Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-14 Ye Gao, Lei Xin, Han Lin, Bin Yao, Tao Zhang, Ai-Jun Zhou, Shu Huang, Jian-Hua Wang, Ya-Dong Feng, Sheng-Hua Yao, Yan Guo, Tong Dang, Xian-Mei Meng, Zeng-Zhou Yang, Wan-Qi Jia, Hui-Fang Pang, Xiao-Juan Tian, Bin Deng, Jun-Ping Wang, Wen-Chuan Fan, Luo-Wei Wang
Background Oesophageal squamous cell carcinoma and adenocarcinoma of the oesophagogastric junction have a dismal prognosis, and early detection is key to reduce mortality. However, early detection depends on upper gastrointestinal endoscopy, which is not feasible to implement at a population level. We aimed to develop and validate a fully automated machine learning-based prediction tool integrating
-
Progress towards elimination of hepatitis C in the UK Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-08 Talha Burki
Abstract not available
-
Cause for concern: the rising incidence of early-onset pancreatic cancer Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-08
Abstract not available
-
Universal hepatitis C virus screening and treatment as part of prenatal care Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-08 Alison D Marshall, Marianne Martinello, Camille Zolopa, Carla Treloar, Sarah Larney
Abstract not available
-
Breaking the unspoken rules of UK training in gastroenterology and hepatology Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-08 Suneil A Raju, Emma G Saunsbury, Yazan Haddadin, Matthew L Cowan
Abstract not available
-
Closing the gender gap in gastroenterology leadership Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-08 Freya J Bowker-Howell, Kamaldeep E Kaur, Suneil A Raju, David S Sanders
Abstract not available
-
Correction to Lancet Gastroenterol Hepatol 2023; 8: 343–55 Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-08
Abstract not available
-
Research in Brief Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-08 Holly Baker
Abstract not available
-
Mayflies: a drama limited by time Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-08 Joe Moody
Abstract not available
-
Jo vs Cancer Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-08 Phoebe Ashley-Norman
Abstract not available
-
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-07 Jason A Tye-Din, A James M Daveson, Gautam Goel, Kaela E Goldstein, Holly L Hand, Kristin M Neff, Alina Popp, Juha Taavela, Markku Maki, Jorma Isola, Leslie J Williams, Kenneth E Truitt, Robert P Anderson
Background A gluten-free diet is insufficient to treat coeliac disease because intestinal injury persists and acute reactions with cytokine release follow gluten exposure. Nexvax2 is a specific immunotherapy using immunodominant peptides recognised by gluten-specific CD4+ T cells that might modify gluten-induced disease in coeliac disease. We aimed to assess the effects of Nexvax2 on gluten-induced
-
Reset after RESET: insights from a negative trial in coeliac disease Gastroenterol. Hepatol. (IF 45.042) Pub Date : 2023-03-07 Heather J Galipeau, Elena F Verdu
Abstract not available
更新日期：2023-05-05
京公网安备 11010802027423号